(:CRY)
Business Focus: N/A
Jan 18, 2022 07:10 am ET
CryoLife Announces Corporate Rebranding and Changes Name to Artivion
ATLANTA, Jan. 18, 2022 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also change its ticker symbol on the New York Stock Exchange to
Nov 09, 2021 03:05 pm ET
CryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum
ATLANTA, Nov. 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available.
Nov 04, 2021 04:05 pm ET
CryoLife Reports Third Quarter 2021 Financial Results
ATLANTA, Nov. 4, 2021 /PRNewswire/ --
Oct 20, 2021 04:10 pm ET
CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2021 Financial Results
ATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results will be released on Thursday, November 4, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Sep 22, 2021 04:25 pm ET
Anthony Semedo Joins CryoLife Board of Directors
ATLANTA, Sept. 22, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony "Tony" Semedo to its Board of Directors effective October 1, 2021.
Aug 31, 2021 04:25 pm ET
CryoLife to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
ATLANTA, Aug. 31, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021. The Company's virtual fireside chat is scheduled to begin at 12:30 p.m. ET.
Aug 02, 2021 04:30 pm ET
CryoLife to Participate in Upcoming Virtual Investor Conferences
ATLANTA, Aug. 2, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming virtual investor conferences.
Jul 29, 2021 04:05 pm ET
CryoLife Reports Second Quarter 2021 Financial Results
ATLANTA, July 29, 2021 /PRNewswire/ --
Jul 29, 2021 08:00 am ET
CryoLife Announces Sale of PerClot to Baxter
ATLANTA, July 29, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has completed the sale of its PerClot product line to a subsidiary of Baxter International, Inc. ("Baxter") (NYSE: BAX ), for up to $60.8 million in cash. Of the $60.8 million, CryoLife will receive up to $45.8 million and Starch Medical, Inc. ("SMI") will receive up to $15.0 million. In this sale, CryoLife has transferred its PerClot product line to Baxter and SMI has agreed to transfer or extend certain rights to Baxter. In add
Jul 15, 2021 04:25 pm ET
CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2021 Financial Results
ATLANTA, July 15, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2021 financial results will be released on Thursday, July 29, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Feb 11, 2021 03:05 pm ET
CryoLife Reports Fourth Quarter and Full Year 2020 Financial Results
ATLANTA, Feb. 11, 2021 /PRNewswire/ --
Jan 28, 2021 07:30 am ET
CryoLife Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2020 Financial Results
ATLANTA, Jan. 28, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2020 financial results will be released on Thursday, February 11, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Nov 19, 2020 07:30 am ET
CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020
ATLANTA, Nov. 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will host a webcast for investors and analysts to discuss progress with the Company's ongoing PROACT Xa trial on December 7, 2020 at 4:00 p.m. EST.
Nov 04, 2020 03:05 pm ET
CryoLife Reports Third Quarter 2020 Financial Results
ATLANTA, Nov. 4, 2020 /PRNewswire/ --
Oct 21, 2020 08:04 am ET
CryoLife Announces Release Date and Teleconference Call Details for 2020 Third Quarter Financial Results
ATLANTA, Oct. 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 third quarter financial results will be released on Wednesday, November 4, 2020 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Aug 06, 2020 08:35 am ET
CryoLife to Participate in Upcoming Virtual Investor Conferences
ATLANTA, Aug. 6, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming virtual investor conferences.
Jul 30, 2020 04:05 pm ET
CryoLife Reports Second Quarter 2020 Financial Results
ATLANTA, July 30, 2020 /PRNewswire/ --
Jul 21, 2020 05:00 pm ET
CryoLife Announces Release Date and Teleconference Call Details for 2020 Second Quarter Financial Results
ATLANTA, July 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 second quarter financial results will be released on Thursday, July 30, 2020 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Jun 19, 2020 07:05 am ET
CryoLife Announces Pricing of $100 Million Convertible Senior Notes Offering
ATLANTA, June 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced the pricing of $100 million aggregate principal amount of 4.250% convertible senior notes due 2025 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). CryoLife also granted the initial purchaser of the Notes an option to purchase, within a 13-day period, beginning on, and including, the date on which
Jun 18, 2020 07:05 am ET
CryoLife Announces Offering of Convertible Senior Notes Due 2025
ATLANTA, June 18, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it intends to offer, subject to market conditions and other factors, $100,000,000 aggregate principal amount of convertible senior notes due 2025 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). CryoLife also intends to grant the initial purchasers of the Notes an option to purchase, within
May 07, 2020 04:05 pm ET
CryoLife Initiates Enrollment in PROACT Xa Clinical Trial
ATLANTA, May 7, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has initiated enrollment in the PROACT Xa clinical trial, a prospective, randomized, trial to determine if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban (Eliquis®) rather than on warfarin.
Apr 30, 2020 04:05 pm ET
CryoLife Reports First Quarter 2020 Financial Results
ATLANTA, April 30, 2020 /PRNewswire/ --
Apr 16, 2020 04:05 pm ET
CryoLife Announces Release Date and Teleconference Call Details for 2020 First Quarter Financial Results
ATLANTA, April 16, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 first quarter financial results will be released on Thursday, April 30, 2020 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Apr 01, 2020 04:01 pm ET
CryoLife Provides Business Update in Response to COVID-19 Pandemic
ATLANTA, April 1, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has taken multiple steps to focus on the health and welfare of its employees, patients, and customers.
Oct 30, 2019 04:05 pm ET
CryoLife Reports Third Quarter 2019 Financial Results
ATLANTA, Oct. 30, 2019 /PRNewswire/ --
Oct 16, 2019 04:35 pm ET
CryoLife Announces Release Date and Teleconference Call Details for 2019 Third Quarter Financial Results
ATLANTA, Oct. 16, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 third quarter financial results will be released on Wednesday, October 30, 2019 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 5:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Sep 18, 2019 08:34 am ET
CryoLife to Participate in the Deutsche Bank 27th Annual Leveraged Finance Conference
ATLANTA, Sept. 18, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in a fireside chat with analysts and investors at the upcoming Deutsche Bank 27th Annual Leveraged Finance Conference on Wednesday, September 25, 2019 at The Phoenician in Scottsdale, AZ.
Sep 11, 2019 04:03 pm ET
CryoLife Enters Into Distribution Agreement with Endospan
ATLANTA, Sept. 11, 2019 /PRNewswire/ -- CryoLife, Inc. ("CryoLife"; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has entered into distribution and credit facility agreements with Endospan, as well as an option agreement to purchase Endospan. Endospan is an Israeli-based, privately-held developer of NEXUS™, the only endovascular stent graft system approved for the repair of both aneurysms and dissections in the aortic arch. The addition of NEXUS to CryoLife's highly differentiated branched aortic stent graft portfolio further st
Aug 29, 2019 08:34 am ET
CryoLife to Participate in Upcoming Investor Conferences
ATLANTA, Aug. 29, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming investor conferences.
Jul 30, 2019 04:05 pm ET
CryoLife Reports Second Quarter 2019 Financial Results
ATLANTA, July 30, 2019 /PRNewswire/ --
Jul 25, 2019 08:34 am ET
CryoLife to Present at Canaccord Genuity 39th Annual Growth Conference
ATLANTA, July 25, 2019 CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019 at the InterContinental Boston Hotel.
Jul 17, 2019 08:34 am ET
CryoLife Announces Release Date and Teleconference Call Details for 2019 Second Quarter Financial Results
ATLANTA, July 17, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 second quarter financial results will be released on Tuesday, July 30, 2019 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Apr 30, 2019 04:05 pm ET
CryoLife Reports First Quarter 2019 Financial Results
ATLANTA, April 30, 2019 /PRNewswire/ --
Apr 17, 2019 05:05 pm ET
CryoLife Announces Release Date and Teleconference Call Details for 2019 First Quarter Financial Results
ATLANTA, April 17, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 first quarter financial results will be released on Tuesday, April 30, 2019 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Apr 17, 2019 07:50 am ET
Report: Exploring Fundamental Drivers Behind Franco-Nevada, ADMA Biologics, GSI Technology, CryoLife, Simpson Manufacturing, and Pioneer Power Solutions — New Horizons, Emerging Trends, and Upcoming D
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Franco-Nevada Corporation (NYSE:FNV), ADMA Biologics Inc (NASDAQ:ADMA),...
Apr 03, 2019 08:30 am ET
CryoLife to Present at 18th Annual Needham Healthcare Conference
ATLANTA, April 3, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at the Westin Grand Central hotel in New York.
Mar 05, 2019 04:00 pm ET
CryoLife to Present at Cowen and Company 39th Annual Health Care Conference
ATLANTA, March 5, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019 at The Boston Marriott Copley Place in Boston.
Feb 13, 2019 06:30 pm ET
CryoLife Reports Fourth Quarter and Full Year 2018 Financial Results
ATLANTA, Feb. 13, 2019 /PRNewswire/ --
Feb 01, 2019 04:00 pm ET
CryoLife Announces Release Date and Teleconference Call Details for 2018 Fourth Quarter and Year-end Financial Results
ATLANTA, Feb. 1, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2018 fourth quarter and year-end financial results will be released on Wednesday, February 13, 2019 after the market closes. On Thursday, February 14, 2019 the Company will hold a teleconference call and live webcast at 8:30 a.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Nov 13, 2018 08:25 am ET
Recent Analysis Shows Brown Forman, CryoLife, Aspen Group, Taylor Devices, Synergy Pharmaceuticals, and Ramco-Gershenson Properties Trust Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Brown Forman Corporation (NYSE:BF.A), CryoLife, Inc. (NYSE:CRY), Aspen...
Oct 31, 2018 05:04 pm ET
CryoLife Reports Third Quarter 2018 Results
ATLANTA, Oct. 31, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the third quarter ended September 30, 2018.
Oct 15, 2018 05:00 pm ET
CryoLife Reports Preliminary Financial Results for Third Quarter 2018 in Anticipation of Discussions with Senior Lenders Regarding Repricing Senior Credit Facility
ATLANTA, Oct. 15, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, in anticipation of discussions with its senior lenders regarding repricing its senior secured credit facility, today announced certain preliminary unaudited financial results for the third quarter of 2018.
Sep 18, 2018 05:00 pm ET
CryoLife to Present at Deutsche Bank 26th Annual Leveraged Finance Conference
ATLANTA, Sept. 18, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Deutsche Bank 26th Annual Leveraged Finance Conference on Tuesday, October 2, 2018 at The Phoenician in Scottsdale, AZ.
Aug 06, 2018 05:30 pm ET
CryoLife Reports Second Quarter 2018 Results
ATLANTA, Aug. 6, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the second quarter ended June 30, 2018.
Jul 26, 2018 08:30 am ET
CryoLife to Present at 38th Annual Canaccord Genuity Growth Conference
ATLANTA, July 26, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 38th Annual Canaccord Genuity Growth Conference on Thursday, August 9, 2018 at the InterContinental Boston Hotel.
Jul 18, 2018 08:30 am ET
CryoLife Announces Release Date and Teleconference Call Details for 2018 Second Quarter Financial Results
ATLANTA, July 18, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2018 second quarter financial results will be released on Monday, August 6, 2018 after the market closes. On Tuesday, August 7, 2018 the Company will hold a teleconference call and live webcast at 8:30 a.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Jun 19, 2018 05:00 pm ET
Marna Borgstrom Joins CryoLife Board of Directors
ATLANTA, June 19, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Marna Borgstrom to its Board of Directors effective immediately.
Jun 11, 2018 05:08 pm ET
CryoLife Announces Peer Review Publication of On-X® Aortic Heart Valve PROACT Study
ATLANTA, June 11, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, today announces the publication of our clinical study entitled "Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement" in a peer-reviewed medical journal, the Journal of the American College of Cardiology. The publication reports outcomes from a multicenter, non-inferiority, two-arm study (the PROACT clinical trial) testing whether, after an On-X mechanical aortic valve replacement (AVR), patients in a High Risk Arm
May 02, 2018 05:24 pm ET
CryoLife Reports First Quarter 2018 Results
ATLANTA, May 2, 2018 /PRNewswire/ --
May 01, 2018 08:04 am ET
CryoLife to Present at Deutsche Bank 43rd Annual Health Care Conference
ATLANTA, May 1, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in a fireside chat presentation at the upcoming Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018, at the Intercontinental Hotel in Boston.
Apr 17, 2018 05:04 pm ET
CryoLife Announces Release Date and Teleconference Call Details for 2018 First Quarter Financial Results
ATLANTA, April 17, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2018 first quarter financial results will be released on Wednesday, May 2, 2018 after the market closes. On Thursday, May 3, 2018 the Company will hold a teleconference call and live webcast at 8:00 a.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Mar 20, 2018 08:04 am ET
CryoLife to Present at 17th Annual Needham Healthcare Conference
ATLANTA, March 20, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at the Westin Grand Central in New York.
Mar 07, 2018 05:13 pm ET
CryoLife Reports Fourth Quarter and Full Year 2017 Results
ATLANTA, March 7, 2018 /PRNewswire/ --
Feb 12, 2018 04:04 pm ET
CryoLife Announces Release Date and Teleconference Call Details for 2017 Fourth Quarter and Year-End Financial Results
ATLANTA, Feb. 12, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2017 fourth quarter and year-end financial results will be released on Wednesday, March 7, 2018 after the market closes. On Thursday, March 8, 2018 the Company will hold a teleconference call and live webcast at 8:00 a.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Dec 01, 2017 04:04 pm ET
CryoLife Completes Acquisition of JOTEC
ATLANTA, Dec. 1, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of JOTEC AG, a German-based, privately-held developer of technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts, focused on aortic repair.
Nov 06, 2017 05:04 pm ET
CryoLife Announces Enrollment of First Patients in BioGlue® Clinical Trial in China
ATLANTA, Nov. 6, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that enrollment has started in the Company's BioGlue clinical trial in China. The results from the trial will serve as the basis of the Company's regulatory submission to the Chinese Food and Drug Administration (CFDA) to gain approval to commercialize BioGlue in China. Patients are currently being enrolled at multiple heart centers in China.
Oct 30, 2017 06:30 pm ET
CryoLife Reports Third Quarter 2017 Results
ATLANTA, Oct. 30, 2017 /PRNewswire/ --
Oct 17, 2017 06:04 pm ET
CryoLife Announces Release Date and Teleconference Call Details for 2017 Third Quarter Financial Results
ATLANTA, Oct. 17, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2017 third quarter financial results will be released on Monday, October 30, 2017 after the market closes. On Tuesday, October 31, 2017, the Company will hold a teleconference call and live webcast at 8:00 a.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Oct 10, 2017 06:00 pm ET
CryoLife Announces Definitive Agreement to Acquire JOTEC
ATLANTA, Oct. 10, 2017 /PRNewswire/ -- CryoLife, Inc. ("CryoLife"; NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has entered into a definitive agreement to acquire JOTEC AG ("JOTEC"). JOTEC is a German-based, privately-held developer of technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts, focused on aortic repair. The combination of CryoLife and JOTEC will create a Company with a broad and highly competitive product portfolio focused on aortic surgery, and wi
Oct 02, 2017 09:04 am ET
Jeffrey H. Burbank Joins CryoLife Board of Directors
ATLANTA, Oct. 2, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced the appointment of Jeffrey H. Burbank to its Board of Directors effective September 29, 2017.
Sep 18, 2017 09:34 am ET
Aug 02, 2017 09:04 am ET
CryoLife to Present at 37th Annual Canaccord Genuity Growth Conference
ATLANTA, Aug. 2, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming 37th Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2017 at the InterContinental Boston Hotel.
Jul 24, 2017 06:04 pm ET
CryoLife Reports Second Quarter 2017 Financial Results
ATLANTA, July 24, 2017 /PRNewswire/ --
Jul 10, 2017 08:54 am ET
CryoLife Announces Release Date and Teleconference Call Details for 2017 Second Quarter Financial Results
ATLANTA, July 10, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that 2017 second quarter financial results will be released on Monday, July 24, 2017 after the market closes. On Tuesday, July 25, 2017 the Company will hold a teleconference call and live webcast at 8:00 a.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Apr 27, 2017 06:00 pm ET
CryoLife to Present at Deutsche Bank 42nd Annual Health Care Conference
ATLANTA, April 27, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3, 2017 at the InterContinental Boston Hotel.
Apr 27, 2017 07:54 am ET
CryoLife Announces On-X Aortic Heart Valve PROACT Study Results to be Presented at American Association for Thoracic Surgery Centennial Meeting
ATLANTA, April 27, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that results from the On-X aortic heart valve PROACT study will be presented in a late-breaking session at the American Association for Thoracic Surgery (AATS) Centennial Meeting, which is being held April 29 to May 3, 2017 at the Hynes Convention Center in Boston, MA.
Apr 26, 2017 06:00 pm ET
CryoLife Reports First Quarter 2017 Financial Results
ATLANTA, April 26, 2017 /PRNewswire/ --
Apr 11, 2017 09:04 am ET
CryoLife Announces Release Date and Teleconference Call Details for 2017 First Quarter Financial Results
ATLANTA, April 11, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that 2017 first quarter financial results will be released on Wednesday, April 26, 2017 after the market closes. On Thursday, April 27, 2017 the Company will hold a teleconference call and live webcast at 8:00 a.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Feb 15, 2017 05:24 pm ET
CryoLife Reports Fourth Quarter and Full Year 2016 Financial Results
ATLANTA, Feb. 15, 2017 /PRNewswire/ --
Feb 07, 2017 08:34 am ET
CryoLife Announces Release Date and Teleconference Call Details for 2016 Fourth Quarter and Year-End Financial Results
ATLANTA, Feb. 7, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that 2016 fourth quarter and year-end financial results will be released on Wednesday, February 15, 2017 after the market closes. On Thursday, February 16, 2017 the Company will hold a teleconference call and live webcast at 8:00 a.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Nov 10, 2016 08:34 am ET
CryoLife to Present at Two Investor Conferences in November 2016
ATLANTA, Nov. 10, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that Pat Mackin, Chairman, President and Chief Executive Officer, will present at two investor conferences in November 2016.
Oct 26, 2016 06:34 pm ET
CryoLife Reports Third Quarter 2016 Financial Results
ATLANTA, Oct. 26, 2016 /PRNewswire/ --
Oct 25, 2016 06:20 pm ET
James W. Bullock Joins CryoLife Board of Directors
ATLANTA, Oct. 25, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced the appointment of James W. Bullock to its Board of Directors effective immediately.
Oct 12, 2016 09:34 am ET
CryoLife Announces Release Date and Teleconference Call Details for 2016 Third Quarter Financial Results
ATLANTA, Oct. 12, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that 2016 third quarter financial results will be released on Wednesday, October 26, 2016 after the market closes. On Thursday, October 27, 2016 the Company will hold a teleconference call and live webcast at 8:00 a.m. ET to discuss the results, followed by a question and answer session hosted by J. Patrick Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Sep 19, 2016 09:34 am ET
CryoLife to Present at Ladenburg Thalmann 2016 Healthcare Conference
ATLANTA, Sept. 19, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016 at the Sofitel Hotel in New York.
Sep 07, 2016 09:34 am ET
CryoLife to Present at Morgan Stanley Global Healthcare Conference
ATLANTA, Sept. 7, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 in New York.
Sep 06, 2016 09:34 am ET
CryoLife Appoints James McDermid as Chief Human Resources Officer
ATLANTA, Sept. 6, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today the appointment of James McDermid to the position of Chief Human Resources Officer, effective immediately. Mr. McDermid joins the company from Medtronic where he was Group Vice President, Human Resources for the Cardiac and Vascular Group. He will report to Pat Mackin, Chairman, President, and Chief Executive Officer.
Aug 11, 2016 09:34 am ET
CryoLife to Present at 2016 Wedbush PacGrow Healthcare Conference
ATLANTA, Aug. 11, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016 in New York.
Aug 04, 2016 06:03 pm ET
CryoLife to Present at 36th Annual Canaccord Genuity Growth Conference
ATLANTA, Aug. 4, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming 36th Annual Canaccord Genuity Annual Growth Conference on Wednesday, August 10, 2016 in Boston, MA.
Jul 25, 2016 06:34 pm ET
CryoLife Reports Second Quarter 2016 Financial Results
ATLANTA, July 25, 2016 /PRNewswire/ --
Jul 12, 2016 06:30 pm ET
CryoLife Announces Release Date and Teleconference Call Details for 2016 Second Quarter Financial Results
ATLANTA, July 12, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that 2016 second quarter financial results will be released on Monday, July 25, 2016 after the market closes. On Tuesday, July 26, 2016 the Company will hold a teleconference call and live webcast at 8:00 a.m. ET to discuss the results, followed by a question and answer session hosted by J. Patrick Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Apr 27, 2016 06:34 pm ET
CryoLife Reports First Quarter 2016 Financial Results
ATLANTA, April 27, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today its results for the first quarter of 2016.
Apr 14, 2016 07:40 am ET
CryoLife Exercises Right to Acquire PhotoFix™ Bovine Pericardium Patch from Genesee BioMedical
ATLANTA, April 14, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it has exercised its right to acquire the PhotoFix™ bovine pericardium patch ("PhotoFix") from Genesee BioMedical, Inc. for $2.3 million in cash. CryoLife acquired the distribution rights and purchase option for PhotoFix in August 2014.
Apr 13, 2016 09:30 am ET
CryoLife Announces Release Date and Teleconference Call Details for 2016 First Quarter Financial Results
ATLANTA, April 13, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that 2016 first quarter financial results will be released on Wednesday, April 27, 2016 after the market closes. On Thursday, April 28, 2016 the Company will hold a teleconference call and live webcast at 8:00 a.m. ET to discuss the results, followed by a question and answer session hosted by J. Patrick Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.
Mar 18, 2016 03:36 pm ET
CryoLife Announces Sale of ProCol® Distribution Rights and Purchase Option to LeMaitre Vascular, Inc.
ATLANTA, March 18, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that LeMaitre Vascular, Inc. (Nasdaq: LMAT) has acquired CryoLife's ProCol Vascular Bioprosthesis ("ProCol") distribution rights and purchase option and has exercised that option to acquire ProCol from Hancock Jaffe Laboratories Inc. ("Hancock Jaffe").
Feb 17, 2016 05:04 pm ET
CryoLife to Present at RBC Capital Markets Global Healthcare Conference
ATLANTA, Feb. 17, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming RBC Capital Markets Global Healthcare Conference on Tuesday, February 23, 2016 at the New York Palace Hotel in New York.
Feb 15, 2016 05:34 pm ET
CryoLife Reports Fourth Quarter and Full Year 2015 Financial Results
ATLANTA, Feb. 15, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today its results for the fourth quarter and full year of 2015.
Feb 04, 2016 08:04 am ET
CryoLife Announces Sale of HeRO Graft to Merit Medical Systems
ATLANTA, Feb. 4, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it sold its HeRO Graft product line to Merit Medical Systems, Inc. (NASDAQ: MMSI) for $18.5 million in cash.
Feb 03, 2016 08:34 am ET
CryoLife Announces Release Date and Teleconference Call Details for 2015 Fourth Quarter and Year End Financial Results
ATLANTA, Feb. 3, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that 2015 fourth quarter and year end financial results will be released on Tuesday, February 16, 2016. On that day, the Company will hold a teleconference call and live webcast at 8:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Pat Mackin, president and chief executive officer of CryoLife, Inc.
Jan 20, 2016 04:15 pm ET
CryoLife Completes Acquisition of On-X Life Technologies Holdings, Inc.
ATLANTA, Jan. 20, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of On-X Life Technologies Holdings, Inc. ("On-X"), an Austin, Texas-based, privately held mechanical heart valve company.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.